First patient dosed in Ph 1 trial of HLX316 in advanced/metastatic solid tumors
Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient has been dosed in a Phase 1 clinical study (HLX316-FIH101) of HLX316, a potential first‑in‑class (FIC) B7‑H3–targeted sialidase fusion protein, in China. This progress marks the official entry of HLX316 into the Phase 1 clinical study stage to evaluate its safety, tolerability, and preliminary efficacy in patients with advanced/metastatic solid tumors.
Share:
More News
Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “HER2-directed therapies have already transformed care for certain HER2-expressing cancers, including breast and gastric cancers. However, many other cancers overexpress HER2, and targeted treatment options remain unavailable for most of these tumour types. This positive CHMP opinion underscores the importance
“Today’s acceptance of the supplemental BLA represents an important milestone for ImmunityBio and for patients with BCG-unresponsive NMIBC,” said Richard Adcock, President and CEO of ImmunityBio. “ANKTIVA is already approved for patients with CIS with or without papillary disease, and this application has the potential to expand access to patients
The first patient was treated with [212Pb]VMT-α-NET in a fourth cohort of the Company’s ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs). This cohort explores optimizing a 20 mCi cumulative dose by front-loading, with 6.0 mCi
“FDA Orphan Drug Designation for CLN-049 emphasizes both the urgent need for new therapies for people living with relapsed or refractory acute myeloid leukemia – including patients with TP53-mutated AML who currently face a particularly poor prognosis – and the potential of this FLT3-directed T cell engager to expand treatment